



Is it COVID-19, flu, RSV, or something else?



Respiratory tests can help you make a precise diagnosis

SARS-CoV-2 (COVID-19), influenza A or B (flu), respiratory syncytial virus (RSV), and other respiratory infections can present with similar symptoms, such as fever, cough, and shortness of breath, but may have different treatment options.

That's why it's important to consider testing for each of these contagious illnesses at the same time—especially when suspecting RSV in high-risk patient populations.

Knowing which infection—or infections—are causing your patient's symptoms will help you determine the best treatment.

Whether caused by COVID-19, influenza, or another respiratory illness, the symptoms can be extremely similar¹:

- Fever or feeling feverish/chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue (tiredness)
- Sore throat
- Runny or stuffy nose
- Muscle pain or body aches
- Headache
- Vomiting and diarrhea in some cases (although more common in children than adults)



For more information, call your sales representative or **1.866.MY.QUEST (1.866.697.8378)**

Combination testing options with Quest Diagnostics

Our testing options use a single specimen to test for common respiratory pathogens, helping to expedite diagnosis so you can develop an appropriate treatment/care plan.

Now available at Quest Patient Service Centers

SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT combination test is available for collection at your local Quest Diagnostics Patient Service Center for patients with mild symptoms. Speak with a Quest Representative about availability in your area.

Visit [QuestDiagnostics.com/COVID-19/HCP](https://www.questdiagnostics.com/COVID-19/HCP) to learn more.



Clinicians are encouraged to consider testing for other viral causes of respiratory illness, such as influenza or RSV, in addition to testing for SARS-CoV-2.²

Identifying the source of infection is the first step in managing patient care




Quest offers the convenience of combination testing for influenza A and B and other respiratory pathogens in conjunction with testing for SARS-CoV-2.

Molecular offerings and panels for respiratory pathogen testing	Test code	CPT® code(s)
SARS-CoV-2 RNA (COVID-19) and Influenza A and B, Qualitative NAAT	31688	87636
SARS-CoV-2 RNA (COVID-19), Influenza A/B and RSV RNA, Qualitative NAAT	39816	0241U (Cepheid) 87637 (Hologic)
SARS-CoV-2 RNA (COVID-19) and Respiratory Viral Panel, Qualitative NAAT	31686	87635, 87633
SARS-CoV-2 RNA (COVID-19) and Respiratory Pathogen Panel, Qualitative NAAT	31687	87635, 87633, 87486, 87581
SARS-CoV-2 RNA (COVID-19), Qualitative NAAT	39448	87635
Molecular respiratory pathogen tests and panels (Non-COVID)	Test code	CPT code(s)
Influenza A and B RNA, Qualitative Real-Time PCR	16086	87502
Respiratory Syncytial Virus (RSV) RNA, Qualitative Real-Time PCR	16047	87634
Influenza A and B and RSV RNA, Qualitative, Real-Time RT-PCR	91989	87631
Respiratory Viral Panel, PCR	95512	87633
Respiratory Pathogen Panel	37444	87633, 87486 (<i>C pneumoniae</i>), 87581 (<i>M pneumoniae</i>)

Components of panels can be ordered separately. The Respiratory Viral Panel, PCR, includes testing for the detection of the following pathogens, all of which can be ordered individually by their specific Quest code: Adenovirus DNA, Qualitative, Real-Time PCR (test code 16046); Influenza A and B Virus with Subtyping, Real-Time PCR (test code 91335); Rhinovirus RNA, Real-Time PCR (test code 40035); Enterovirus RNA, Qualitative, Real-Time PCR (test code 15082); and Human *Metapneumovirus* RNA, Qualitative, Real-Time PCR (test code 40034). The Respiratory Pathogen Panel includes all the previous tests listed for the Respiratory Viral Panel as well as Parainfluenza Virus (Types 1, 2, 3, and 4) RNA, Qualitative, Real-Time PCR (test code 91228); *Chlamydomphila pneumoniae* DNA, Qualitative, Real-Time PCR (test code 16003); and *Mycoplasma pneumoniae* DNA, Qualitative, Real-Time PCR (test code 15498).

Visit our [test directory](#) to learn more about our complete portfolio of respiratory infection tests 

Count on Quest: the right test for the right patient for faster diagnosis and treatment

<p>Leadership </p> <p>A diagnostic leader during global health crises, Quest introduced a COVID-19 test 2 days before the virus was labeled a worldwide pandemic. We continue to deliver diagnostic insights to support the fight against COVID-19 and other conditions that impact patient lives.</p>	<p>Convenience </p> <p>Labs are available nationwide to support increased testing volume in approximately 2,000 Patient Service Centers. Quest also provides integration with most electronic health records (EHRs) through Quanam® Lab Services Manager.</p>	<p>History and expertise </p> <p>Quest has 4 decades of experience leading infectious disease testing during public health emergencies, with experts available to help interpret test results.</p>
--	---	--

 Contact your Quest Diagnostics sales representative at **1.866.MY.QUEST (1.866.697.8378)**

- The Quest Diagnostics molecular test, the other authorized molecular tests (together the “molecular tests”), the COVID/Flu molecular test, the COVID/Flu/RSV test, (together “the tests”) have not been FDA cleared or approved;
- The tests have been authorized by FDA under an EUA for use by authorized laboratories;
- The molecular tests have been authorized only for the unsupervised self-collection and maintenance of nasal specimens for the detection of nucleic acid from SARS CoV-2, not for any other viruses or pathogens;
- The COVID/Flu molecular test has been authorized only for the unsupervised self-collection and maintenance of nasal specimens as an aid in detection of nucleic acid from SARS-CoV-2 and influenza A virus and influenza B virus, not for any other viruses or pathogens;
- The COVID/Flu/RSV test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acids from SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV), and not for any other viruses or pathogens;
- The tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

References:
 1. CDC. Similarities and differences between flu and COVID-19. Last reviewed March 20, 2024. Accessed August 29, 2024. <https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm>
 2. CDC. Clinical guidance for hospitalized and non-hospitalized patients when SARS-CoV-2 and influenza viruses are co-circulating. Last reviewed December 6, 2023. Accessed August 26, 2024. <https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians.htm>

Image content features models and is intended for illustrative purposes only.
 Test codes may vary by location. Please contact your local laboratory for more information.
 The CPT® codes provided are based on American Medical Association guidelines and are for informational purposes only.
 CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.